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ABSTRACT 
Objective: To develop a rapid, sensitive, accurate, precise and linear Reverse Phase High Performance Liquid Chromatographic (RP-HPLC) method 
and validate as per ICH guidelines for the quantitative estimation of Dabigatran etexilate mesylate in capsules.  
Methods: The optimized method uses a reverse phase column, Waters Symmetry C18 (250 X 4.6 mm; 5μ), a mobile phase of tri ethylammonium 
phosphate buffer (pH 2.5):acetonitrile in the proportion of 40:60 v/v, flow rate of 1.0 ml/min and a detection wavelength of 313 nm using a UV 
detector.  
Results: The developed method resulted in Dabigatran etexilate mesylate eluting at 2.44 min. It exhibited linearity in the range 15-45μg/ml. The 
precision is exemplified by relative standard deviation of 0.05%. Percentage mean recovery was found to be in the range of 98-102, during accuracy 
studies. The limit of detection (LOD) and limit of quantitation (LOQ) was found to be 39.19μg/ml and 118.88μg/ml respectively. 
Conclusion: A sensitive, rapid, accurate, precise and linear RP-HPLC method was developed and validated for the quantitative estimation of 
Dabigatran etexilate mesylate in capsules as per ICH guidelines and hence it can be used for the routine analysis in various pharmaceutical 
industries.  
Keywords: RP-HPLC, Dabigatran etexilate mesylate, Method development, Validation. 
 
Dabigatran etexilate (DE) is the oral prodrug of the active moiety 
dabigatran. The dabigatran etexilate pro-drug was developed due to 
the limited oral availability of dabigatran, and it is converted into 
dabigatran (DAB) in vivo via esterases enzyme. The drug substance 
is the mesylate salt form of the prodrug, called dabigatran etexilate 
mesylate (DEM) (fig. 1). The chemical name (IUPAC) of dabigatran 
etexilate mesylate is ethyl-N-{[2-({[4-((E)-amino {[(hexyloxy) 
carbonyl] imino} methyl) phenyl] amino} methyl)-1-methyl-1H-benz 
imidazol-5-yl] carbonyl}-Npyridin-2-yl-β-alaninate methane-
sulfonate [1] corresponding to the molecular formula C
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Dabigatran is an oral anticoagulant drug that acts as a direct 
thrombin (factor IIa) inhibitor. It was developed by the 
pharmaceutical company Boehringer Ingelheim. It is an 
anticoagulant medicine used for the prevention of clots and emboli 
after orthopedic surgery (hip or knee replacement) and to prevent 
stroke and other systemic emboli in people with non-valvular atrial 
fibrillation (AF), a commonly occurring abnormal heart rhythm [2]. 
Few analytical methods are reported for the determination of 
Dabigatran etexilate by UV [3], LC/MS [4] and UPLC MS/MS [5] in 
bulk and/or plasma. While only two stability indicating assay 
methods are cited in the literature using HPLC in bulk [1,6] and only 
two methods in formulations [7, 8]. Literature reveals use of 
potassium dihydrogen orthophosphate as buffer (pH 4.5and pH 7.0) 
and triethyl ammonium phosphate buffer (pH 6.0) along with 
organic modifier as mobile phase for assay methods in formulations 
using RP-HPLC. As there is no literature reported on working at 
acidic pH using triethyl ammonium phosphate buffer (pH 2.5), we 
here report a new and a  rapid RP-HPLC validated method for the 
quantitative estimation of Dabigatran etexialte in capsules using 
triethyl ammonium phosphate buffer (pH 2.5) along with 
acetonitrile as mobile phase.  
Chemicals and reagents 
Analytically pure sample of Dabigatran etexilate mesylate with 
purity 95% was obtained as gift sample from Chandra labs, 
Hyderabad, India and tablet formulation [PRADAXA] capsules was 
procured from Apollo Pharmacy, Hyderabad, India with labelled 
amount of 110 mg of Dabigatran etexilate mesylate. Acetonitrile 
(HPLC grade), water (HPLC grade), Triethylamine (AR Grade) and 
ortho phosphoric acid (AR Grade) were obtained from SD Fine 
chemicals (Hyderabad, India), 0.45 and 0.22μm Nylon membrane 
filters were obtained from Spincotech Private Limited, Hyderabad, 
India. 
 
Fig. 1: Structure of dabigatran etexilate mesylate 
 
 Instrument 
HPLC analysis was performed on Shimadzu LC-20AD Prominence 
Liquid Chromatography comprising a LC-20AD pump, Shimadzu 
SPD-20A Prominence UV-VISIBLE detector and a reverse phase C18 
column, Waters Symmetry (250 X 4.6 mm; 5μ). A manually operating 
Rheodyne injector with 20 μL sample loop was equipped with the 
HPLC system. The HPLC system was controlled with “Lab solutions 
lite” software. A double beam UV-visible spectrophotometer 
(Shimadzu, model UV-1800) having two matched quartz cells with 1 
cm light path and loaded with UV probe software (version 2.41) was 
used for recording of spectra and measuring absorbance. An 
electronic analytical weighing balance (0.1 mg sensitivity, Shimadzu 
AY 220), digital pH meter (DELUX model 101), a sonicator (sonica, 
model 2200 MH).  
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Selection of wavelength 
Suitable wavelength for the HPLC analysis was determined by 
recording UV spectrum in the range of 200-400 nm for Dabigatran. 
Suitable wavelength selected was 313 nm (fig. 2). 
Chromatographic conditions 
The developed method uses a reverse phase C18 column, Waters 
Symmetry C18 (250 X 4.6 mm; 5μ), mobile phase of triethyl 
ammonium phosphate buffer (pH 2.5): acetonitrile in the proportion 
of 40:60 v/v. The mobile phase was set at a flow rate of 1.0 ml/min 
and the volume injected was 20μl for every injection. The detection 
wavelength was set at 313 nm. 
 
 
Fig. 2: UV spectrum of dabigatran etexilate mesylate 
 
Buffer preparation 
The buffer solution was prepared by adding 5 ml of triethylamine to 
1000 ml of HPLC grade water and later pH was adjusted to 2.5 using 
30% v/v of ortho phosphoric acid in water. The buffer was then 
filtered through 0.45 μm nylon membrane filter.  
Mobile phase preparation 
The mobile phase was prepared by mixing buffer and acetonitrile in 
the ratio of 40:60 v/v and later it was sonicated for 10 min for the 
removal of air bubbles.  
Preparation of stock and working standard solution 
10 mg of Dabigatran etexilate mesylate was accurately weighed and 
taken in 100 ml clean and dry volumetric flask containing 50 ml of 
diluent (same as mobile phase) and then sonicated for 2 min to 
dissolve. Later the solution was made up to the mark using the 
mobile phase. This is considered as stock standard solution 
(100µg/ml). From the stock solution, 3 ml was pipetted out and to 
10 ml using the mobile phase to get a concentration of 30µg/ml, 
treated as 100% target concentration.  
Preparation of stock and working sample solution 
Not less than 20 capsules were taken, emptied and test stock 
solution of Dabigatran etexilate mesylate (275 μg/ml) was prepared 
by transferring weight equivalent to 27.5 mg of Dabigatran etexilate 
mesylate to 80 ml of mobile phase which is sonicated for 5 min and 
later made up to 100 ml with mobile phase. This solution was 
filtered using 0.22micron syringe filter. From the above stock 
solution 1.09 ml was pipetted out and made up to 10 ml to get 
working sample solution equivalent to a concentration of 30µg/ml 
for Dabigatran etexilate mesylate, concentration equal to 100% 
target concentration. 
RESULTS AND DISCUSSION 
Method development 
A Reverse phase HPLC method was developed keeping in mind the 
system suitability parameters i.e. tailing factor (T), number of 
theoretical plates (N), runtime and the cost effectiveness. The 
optimized method developed resulted in the elution of Dabigatran 
etexilate mesylate at 2.44 min. Fig. 3 and 4 represent 
chromatograms of blank solution and standard solution (30µg/ml) 
respectively. The total run time is 5 min. System suitability tests are 
an integral part of method development and are used to ensure 
adequate performance of the chromatographic system. Retention 
time (RT), number of theoretical plates (N) and peak Tailing factor 
(T) were evaluated for injection of the standard at working 
concentration. The results are given in table 1. 
 
Table 1: System suitability studies results 
Parameters Dabigatran etexilate 
mesylate 
Retention time (min) 2.44 
Number Of Theoretical plates (N) 3797 
Tailing factor (T) 1.739 
 
 
Fig. 3: Typical chromatogram of blank solution 
 
 
Fig. 4: Typical chromatogram of the standard solution 
 
In order to test the applicability of the developed method to a 
commercial formulation, PRADAXA was chromato graphed at 
working concentration (30µg/ml) and it is shown in fig. 5. The 
sample peak was identified by comparing the retention time with 
the standard drug fig. 4. System suitability parameters were within 
the acceptance limits, ideal for the chromato graphed sample. 
Integration of separated peak area was done and drug concentration 
was determined by using the peak area concentration relationship 
obtained in the standardization step. The protocol affords 
reproducible assay of the drug in the sample ranging between 98 
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Fig. 5: Typical chromatogram for the tablet formulation 
 
Method validation 
Validation of the analytical method is the process that establishes by 
laboratory studies in which the performance characteristics of the 
method meet the requirements for the intended analytical 
application. RP-HPLC method developed was validated according to 
International Conference on Harmonization (ICH) guidelines [9] for 
validation of analytical procedures. The method was validated for 
the parameters like system suitability, specificity, linearity, accuracy, 
precision, and ruggedness, limit of detection (LOD) and limit of 
quantitation (LOQ). 
Specificity 
Fig. 3-5 for blank, standard drug solution and sample chromatogram 
reveal that the peaks obtained in the standard solution and sample 
solution at working concentrations are only because of the drug as 
blank has no peak at the retention time of Dabigatran etexilate 
mesylate. Accordingly it can be concluded that, the method 
developed is said to be specific. 
Precision 
System precision 
Six replicate injections of the standard solution at working 
concentration showed % RSD (Relative Standard Deviation) less 
than 2 concerning peak area for the drug, which indicates the 
acceptable reproducibility and thereby the precision of the system. 
System precision results are tabulated in table 2. 
Method precision 
Method precision was determined by performing assay of sample 
under the tests of repeatability (Intraday precision) and 
intermediate precision at working concentration.  
Repeatability (Intraday precision) 
Six consecutive injections of the sample from the same 
homogeneous mixture at working concentration showed % RSD less 
than 2 concerning % assay for the drug which indicate that the 
method developed is method precise by the test of repeatability and 
hence can be understood that the method gives consistently 
reproducible results (table 3).  
 
Table 2: System precision results of dabigatran etexilate 
mesylate 
Injection no. (n) RT Peak area 
1 2.443 962.79 
2 2.442 962.87 
3 2.443 961.04 
4 2.443 961.22 
5 2.446 961.08 
Average 2.443 961.8 
Standard Deviation 0.001 0.943 
%RSD 0.061 0.098 
 
Table 3: Intraday precision results of dabigatran etexilate mesylate 
n  RT Peak area % Assay 
1 2.441 1018.95 100.64 
2 2.441 1019.16 100.66 
3 2.401 1007.82 99.54 
4 2.441 1019.16 100.66 
5 2.441 1018.36 100.58 
6 2.46 1007.82 99.54 
Average 2.437 1015.21 100.27 
Standard deviation 0.019 5.733 0.566 
%RSD 0.798 0.564 0.055 
 
Intermediate precision 
Intermediate precision was evaluated by performing assay of the 
formulations by different analyst on a different day by injecting six 
consecutive injections of the sample at working concentration from 
the same homogeneous mixture of tablets. This study showed % RSD 
less than 2 concerning % assay for both the drugs which indicate 
that the method developed is rugged and hence can be understood 
that the method gives reproducible results irrespective of analyst 
(table 4). 
 
Table 4: Inter day precision results of dabigatran etexilate mesylate 
n RT Peak area % Assay 
1 2.47 997.99 98.57 
2 2.47 998.82 98.65 
3 2.47 997.99 98.57 
4 2.47 995.23 98.30 
5 2.47 997.52 98.46 
6 2.47 993.39 98.12 
Average 2.47 995.02 98.28 
Standard deviation 0 4.553 0.449 
%RSD 0 0.456 0.045 
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Standard solutions of Dabigatran etexilate mesylate at different 
concentrations level (50%, 75%, 100%, 125% and 150%) were 
prepared. Calibration curve was constructed by plotting the 
concentration level of drug versus corresponding peak area.  
The results show an excellent correlation between peak area and 
concentration level of drug within the concentration range (15-
45µg/ml) for the drug and the results are given in table 5 and fig. 6.  
The correlation coefficient of Dabigatran etexilate mesylate is 0.996 
and hence the method is said to be linear. 
 
Table 5: Calibration data of dabigatran etexilate mesylate 
% Level Concentration (µg/ml) Peak area 
50 15 495.09 
75 22.5 695.8 
100 30 973.48 
125 37.5 1218.32 
150 45 1509.63 
Regression coefficient  0.996 
Regression equation  y=34.021x-42.176 
 
Table 6: Results of accuracy studies for dabigatran etexilate mesylate 
% Level Peak area %Recovery % Mean recovery %RSD 
50 525.81 100.87   
 525.78 100.84 101.19 0.573 
 525.96 101.87   
100 1018.95 100.64   
 1019.16 100.66 100.63 0.242 
 1018.36 100.58   
150 1584.63 101.3   
 1585.38 101.2 100.56 1.173 
 1509.63 99.2   
 
 
Fig. 6: Linearity graph of dabigatran etexilate mesylate 
 
Accuracy 
Accuracy was determined by means of recovery experiments, by the 
determination of % mean recovery of sample at three different 
levels (50-150%). At each level, three determinations were 
performed. Percent mean recovery was calculated as shown in table 
6. The accepted limits of recovery are 98%-102% and all observed 
data are within the required range which indicates good recovery 
values and hence the accuracy of the method developed. 
Sensitivity 
The sensitivity of measurement of Dabigatran etexilate mesylate by 
use of the proposed method was estimated in terms of the limit of 
quantitation (LOQ) and the limit of detection (LOD). LOQ and LOD 
were calculated by the use of the equations LOD = 3.3σ/S and LOQ = 
10σ/S where σ is the standard deviation of response of calibration 
plot and S is the slope of the corresponding calibration plot. The 
limit of detection (LOD) and limit of quantitation (LOQ) was found to 
be 39.19μg/ml and 118.88μg/ml respectively. 
CONCLUSION 
A reverse phase HPLC isocratic method developed has been 
validated as per ICH guidelines in terms of specificity, accuracy, 
precision, and linearity, limit of detection and limit of quantitation, 
for the quantitative estimation of Dabigatran etexilate mesylate in 
tablets. The precision is exemplified by relative standard deviation 
of 0.05%. A good linear relationship was observed for the drug 
between concentration ranges of 15 and 45µg/ml. Accuracy studies 
revealed that mean recoveries were between 98 and 102%, an 
indicative of accurate method. The limit of detection (LOD) and limit 
of quantitation (LOQ) was found to be 39.19(μg/ml and 
118.88μg/ml respectively. Accordingly it can be concluded that the 
developed reverse phase isocratic HPLC method is sensitive, 
accurate, precise and linear and therefore the method can be used 
for the routine analysis of Dabigatrn etexilate mesylate in capsules. 
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